Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 26, 2018January 26, 2018

Safety Board OKs Continuation of Phase 2b Trial of Lanifibranor as a Systemic Sclerosis Treatment

News

A data safety monitoring board (DSMB) has recommended that Inventiva continue its Phase 2b clinical trial assessing lanifibranor (previously known as IVA337) for the treatment of diffuse cutaneous scleroderma, after reviewing data gathered in ... Read more

January 11, 2018January 11, 2018

Harvard Researchers Explore Cellular Self-destruction as Scleroderma Treatment

News

Organ fibrosis in scleroderma patients might be reversed with treatments that allow fibrotic cells to self-destruct, Harvard scientists suggest. Their study, “Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 ... Read more

January 4, 2018January 4, 2018

Corbus Readies Pivotal Phase 3 Trial of Anabasum, Possible Scleroderma Treatment

News

Corbus Pharmaceuticals is planning a global Phase 3 trial to assess anabasum (JBT-101) as a treatment for scleroderma. If successful, the company plans to apply to regulatory authorities, asking ... Read more

November 28, 2017November 28, 2017

Researchers Find Way to Block Receptor Believed to Be at the Root of Autoimmune Diseases

News

University of Colorado researchers have discovered a molecule that prevents the activation of a receptor that scientists believe is involved in autoimmune diseases. The team at university’s BioFrontiers Institute used the ... Read more

November 21, 2017November 21, 2017

Scleroderma Patients Have Stiffer Than Normal Hand Nerves, Researchers Find

News

Scleroderma patients’ nerve-related hand problems, including numbness, tingling and pain, may stem from the main nerve to the hands becoming stiffer than normal, according to Turkish researchers. The team ... Read more

November 6, 2017November 6, 2017

Corbus Offers Update of Scleroderma Therapy Anabasum at Ongoing ACR Meeting

News

Corbus Pharmaceuticals is sharing a host of data on anabasum (JBT-101) for the treatment of diffuse cutaneous scleroderma at the ongoing American College of Rheumatology (“ACR”) 2017 Annual Meeting in San ... Read more

October 31, 2017October 31, 2017

Scleroderma Autoantibodies Might Reveal More About Disease Profiles Than Current Classification

News

Specific autoantibodies may give rise to clear differences in disease features among Spanish patients with scleroderma, according to a report in the journal Clinical and Experimental Rheumatology. These differences ... Read more

August 15, 2017

Corbus to Start Phase 3 Anabasum Trial in Scleroderma Patients by Year’s End

News

Corbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the fourth quarter of 2017, putting the treatment a step closer toward ... Read more

July 26, 2017July 26, 2017

Cytori’s Habeo Cell Therapy Appears to Benefit Scleroderma Patients with Diffuse Form of the Disease

News

Cytori Therapeutics’ Habeo Cell Therapy may be effective only in scleroderma patients who have the more severe diffuse version of the disease, a Phase 3 clinical trial indicates. The ... Read more